Cost-effectiveness analysis of laparoscopic versus open distal gastrectomy for locally advanced gastric cancer based on TNM stage: a Markov model
- 6 March 2026
- journal article
- research article
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (5) , 4184-4194
Abstract
Background Although laparoscopic distal gastrectomy (LDG) and open distal gastrectomy (ODG) show comparable short- and long-term efficacy for treating locally advanced gastric cancer (LAGC), evidence on the cost-effectiveness of LDG versus ODG remains limited. This study aimed to evaluate the long-term cost-effectiveness of LDG versus ODG in patients with LAGC at different stages from a societal perspective in China. Methods A Markov model incorporating three health states (stable disease, disease progression, and death) was constructed based on data from the CLASS-01 trial. The outcome measures included incremental cost-effectiveness ratio (ICER) and quality-adjusted life years (QALYs). Cost-effectiveness was assessed by comparing the ICER to the willingness-to-pay (WTP) threshold. Sensitivity analyses were conducted to evaluate model uncertainty. Results In stage I patients, the model projected that LDG provided 0.29 incremental QALYs at an incremental cost of $819.33, yielding an ICER of $2829.98/QALY—below the WTP threshold, indicating potential cost-effectiveness conditional on the model parameters. Conversely, in stage II and III patients, ODG was associated with higher QALY gains than LDG (simulated incremental QALYs of − 0.14 and − 0.22, respectively), and the ICERs were negative (stage II: ICER − $7692.45 per QALY, incremental cost $1073.62; stage III: ICER − $4232 per QALY, incremental cost $913.41), suggesting that ODG was the cost-effective strategy within the simulation framework. Sensitivity analyses indicated that base-case findings were robust to parameter uncertainty. Conclusion Based on the model’s assumptions and parameterization, the simulated results indicate that LDG is likely cost-effective in stage I patients, while ODG appears more advantageous in stage II and III patients.Keywords
This publication has 32 references indexed in Scilit:
- Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT)Annals of Surgery, 2019
- Association of Hospital Costs With Complications Following Total Gastrectomy for Gastric AdenocarcinomaJAMA Surgery, 2017
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016
- Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled TrialJournal of Clinical Oncology, 2016
- A cost-effectiveness comparison between early surgery and non-surgical approach for incidental papillary thyroid microcarcinomaEuropean Journal of Endocrinology, 2015
- Outcomes After Laparoscopic or Open Distal Gastrectomy for Early-Stage Gastric CancerAnnals of Surgery, 2013
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Prediction of Recurrence of Early Gastric Cancer After Curative ResectionAnnals of Surgical Oncology, 2009
- Development of WHO guidelines on generalized cost-effectiveness analysisHealth Economics, 2000